Sponsored by Market IQ Media Group*

Big moves in biotech today, folks. ONCY just got a fresh “BUY” rating, and it’s catching some serious attention from big pharma giants like Roche and Pfizer. This one’s got momentum, and if you like tactical plays with solid backing, you’ll want to keep reading.

TODAY’S TOP ALERT! 

Oncolytics Biotech (Nasdaq: ONCY)

👉  ONCY is TODAY’S #1 ALERT 👈

Hey Folks,

I hope you’re having a great morning and that you’re fully prepared for the trading day ahead (☕☕☕).

Stock futures are about even as of this writing, so I think it’s an especially good day to look for opportunities on smaller stocks.

My “tactical trade” idea today is one I last alerted the Monday before Christmas. It went on to surge as high as 28% over the course of the week.

Five of the six “tactical” ideas I’ve alerted this week have been double-digit winners, so I’m hoping this will be another. 🤞

Go ahead and pull up Oncolytics Biotech Inc. (ONCY) on your favorite trading platform.

👉  ONCY is TODAY’S #1 ALERT 👈

You’ll see that the stock has had a slight runup since Tuesday and that it’s moved considerably above the 20-day moving average.

You’ll also notice that the stock price has just started to move back above the 20-hour level as well. 

If you have followed me for any length of time, you know I refer to this as a “Gamma Trigger” setup, and it is probably my favorite signal to look for…

Pull up ONCY on your main platform right now, and keep a close eye on it today.

The price action may be helped by Zacks Equity Research upgrading ONCY to a “BUY” yesterday based on its earnings outlook.

Just 20% of Zacks-covered stocks (and it covers more than 4,000) get a “BUY” rating or better.

As Zacks explains, this rating upgrade implies “that the stock might move higher in the near term.”

I think the wind is at ONCY’s back and that it may be escaping oversold territory.

The stock has attracted considerable analyst coverage, and even the lowest recent price target anticipates the stock multiplying more than 4x from yesterday’s close.

For some background, ONCY is a clinical-stage biotechnology company at the leading edge of immunotherapy cancer research.

In case you don’t know, immunotherapy treatments activate the body’s own immune system in order to fight cancer.

At the core of ONCY’s approach is Pelareorep, a reovirus that the company says has “the power to awaken the immune system and unlock its antitumor potential.”

Pelareorep is delivered to the patient intravenously (unlike other immunotherapies which require direct injection into the tumor).

The reovirus then selectively replicates in the cancer cells, inducing “a cascade of inflammatory responses that enable the immune system to destroy the tumor while sparing normal tissue.”

According to the company, “Because pelareorep replicates only in tumor cells, it is well-tolerated by patients.”

The therapy has demonstrated tremendous potential, earning it Fast Track designation from the FDA for the treatment of metastatic breast cancer (mBC) and a type of advanced pancreatic cancer.

Fast Track is “a designation . . . of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need.”

And that designation appears to be paying off…

ONCY has several ongoing “Phase 2” trials — trials that test the treatment in human patients — and has already demonstrated positive results in breast and pancreatic cancers.

To date, the therapy has been studied in more than 1,100 patients.

According to the company, “When pelareorep was added to standard metastatic breast cancer treatment, overall survival rates nearly doubled in a randomized study of patients with HR+/HER2- breast cancer.” (emphasis added)

In fact, the company couldn’t even calculate the median overall survival because more than half of the patients were still alive at the end of the study.

The company said the results were “a remarkable achievement for us” and led it to declare that pelareorep “is efficacious in heavily pre-treated breast cancer patients"

In a pancreatic cancer trial, “Interim clinical data showed a 69% objective response rate, which is nearly triple historical control trial averages.”

This promise at targeting pancreatic cancer led the Pancreatic Cancer Action Network (PanCAN) to award ONCY with a $5 million grant to further its trial.

Going forward, the company plans to continue its ongoing trials as well as initiate “a large Phase 2 study designed to support an accelerated approval” for pelareorep in mBC…

It expects enrollment in the registration-enabling study to begin in the first half of this year.

According to its most recent filing, as of September 30, “the Company reported $19.6 million in cash and cash equivalents. The Company has a projected cash runway through key milestones and into 2025.”

The company has published impressive projected sales figures for pelareorep for treatment of breast cancer:

(See slide 8 here for its key assumptions.)

ONCY has already teamed up with pharma heavyweights such as Roche Holding AG, Pfizer Inc., Merck Serono, Incyte Corporation, and Adlai Nortye to evaluate pelareorep in combination with other therapeutic agents, and there’s no telling where those relationships could lead…

On December 23, the company put out a press release that reads almost like a shareholder letter…

It’s worth reading in its entirety for a great idea of where the company stands. Here are some highlights:

The company said it “expects additional data readouts across our clinical development program in 2025” which form what it believes “is a clear pathway to future commercialization opportunities.”

Those will follow the already-released “robust efficacy results” from its BRACELET-1 breast cancer study.

“In addition,” interim CEO Wayne Pisano said, “our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field.”

Based on their insights, “we believe pelareorep has the potential to become a transformational immunotherapy.”

The press release also noted ONCY’s collaboration with Roche, which will extend to a registration-enabling study of ONCY’s lead candidate in metastatic pancreatic ductal adenocarcinoma (PDAC).

Not surprisingly, ONCY has drawn significant coverage from analysts, including Raymond James, RBC Capital, and Canaccord Genuity…

Their average 12-month price target is $4.80, which is a whopping 548% upside from its current price:

The lowest recent price target among the analysts is still more than 450% higher than its current price.

As you do your own research on this promising company, you’ll want to review this corporate presentation released in December, as well as the company’s very accessible and informative website.

And of course, always approach your trading responsibly, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: For a clinical-stage biotech, ONCY has attracted considerable analyst coverage, and they all expect the stock to multiply over the next 12 months.

The company has collaborated with the likes of Roche, Pfizer, and Merck, and is in ongoing discussions with potential partners.

ONCY is my #1 stock alert today. Keep it at the top of your radar!

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now. 

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty five thousand dollars (cash) from Market IQ Media Group for advertising Oncolytics Biotech Inc for a three-day marketing program starting on February 6, 2025. Prior to this, we received thirty five thousand dollars (cash) from Market IQ Media Group for advertising Oncolytics Biotech Inc for a three-day marketing program starting on December 23, 2024 and also twenty thousand dollars by ach bank transfer by Axe Communications for advertising Oncolytics Biotech Inc for a one-day advertising program. This was paid by someone else not connected to Oncolytics Biotech Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our marketing program ends, though that is not always the case.

Now, diving right into Oncolytics Biotech Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.